Alpha 1-antitrypsin deficiency differential diagnosis: Difference between revisions
Mazia Fatima (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) No edit summary |
||
Line 217: | Line 217: | ||
! colspan="2" rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Classification of jaundice based on etiology | ! colspan="2" rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Classification of jaundice based on etiology | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ||
! colspan=" | ! colspan="5" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |History and clinical manifestations | ||
! colspan="8" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ! colspan="8" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ||
|- | |- | ||
Line 228: | Line 228: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |RUQ Pain | ! style="background:#4479BA; color: #FFFFFF;" align="center" |RUQ Pain | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Pruritis | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Pruritis | ||
!Hepatomegaly | |||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |AST | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |AST | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |ALT | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |ALT | ||
Line 242: | Line 243: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
Line 256: | Line 258: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| -/+ | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
Line 270: | Line 273: | ||
!-/+ | !-/+ | ||
!- | !- | ||
!+ | |||
!↑ | !↑ | ||
!↑ | !↑ | ||
Line 285: | Line 289: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| -/+ | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
Line 299: | Line 304: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| -/+ | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N |
Revision as of 17:50, 12 December 2017
Alpha 1-antitrypsin deficiency Microchapters |
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Alpha 1-antitrypsin deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency differential diagnosis |
FDA on Alpha 1-antitrypsin deficiency differential diagnosis |
CDC on Alpha 1-antitrypsin deficiency differential diagnosis |
Alpha 1-antitrypsin deficiency differential diagnosis in the news |
Blogs on Alpha 1-antitrypsin deficiency differential diagnosis |
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Alpha 1-antitrypsin deficiency has to be differentiated from other conditions with similar presentation like autoimmune hepatitis, bronchiectasis, bronchitis, chronic obstructive pulmonary disease (COPD),cystic fibrosis,emphysema,primary ciliary dyskinesia (Kartagener Syndrome),viral hepatitis.
Differentiating Alpha 1-antitrypsin deficiency from Other Diseases
Alpha 1-antitrypsin deficiency presents with symptoms of
Differential diagnosis of jaundice and Right upper quadrant abdominal pain includes
Jaundice and RUQ pain differential diagnosis are:
|
The differential diagnosis of jaundice, fever, and RUQ pain are:
|
Differential Diagnoses of Alpha 1-antitrypsin deficiency includes:
- Autoimmune Hepatitis
- Bronchiectasis
- Bronchitis
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Emphysema
- Primary Ciliary Dyskinesia (Kartagener Syndrome)
- Viral Hepatitis